Llusern Scientific Announces Key Appointments to Strengthen its Executive Team
CARDIFF, United Kingdom, July 22, 2025 (GLOBE NEWSWIRE) -- Llusern Scientific, a point-of-care diagnostics company, today announces the appointments of Bob Yang as Chief Medical Officer (CMO), Maddy Kennedy as Chief Financial Officer (CFO), and Mark Preston as Chief Technology Officer (CTO). These strategic appointments strengthen Llusern's leadership team as the company builds on its recent ISO 13485 certification and progresses towards IVDR certification, positioning Lodestar DX for upcoming commercial launches across Europe for treatment-directing diagnosis of urinary tract infections (UTIs).
Bob Yang joins Llusern Scientific as Chief Medical Officer. A highly accomplished urology consultant, Mr. Yang brings extensive expertise in complex and recurrent UTIs and male and female incontinence. He has made significant contributions to antibiotic-free treatment options for recurrent UTIs and has been pioneering research in sub-lingual UTI vaccines and male incontinence devices. His expertise will directly complement Llusern's mission to revolutionize UTI diagnostics and support antimicrobial stewardship through the Lodestar DX system, a rapid diagnostic platform designed to enhance clinical decision-making. He is Lead Editor for Springer Nature academic textbooks on Urinary Tract Infections and Male Incontinence, solidifying his standing as one of the global leaders in urological research and practice. Mr. Yang continues to pioneer in his field as a urology consultant at the Royal Berkshire NHS Foundation Hospital and an Associate Lecturer at Oxford University.
'Joining Llusern Scientific is an exciting opportunity to contribute to the growth of innovative diagnostic solutions that will improve patient outcomes globally,' said Bob Yang, Chief Medical Officer of Llusern Scientific. 'The Lodestar DX system offers clinicians a powerful tool to make precise treatment decisions in a single visit, thereby enabling them to combat antimicrobial resistance through improved antibiotic stewardship.'
As Chief Financial Officer, Maddy Kennedy brings over 25 years of experience in financial strategy, investor relations, and corporate governance to Llusern Scientific. She will play a crucial role in supporting Llusern's fundraising activities and steering its expansion into global markets. Known for her ability to translate complex development programs into clear financial plans, Maddy has successfully guided life sciences and technology businesses through strategic growth, M&A, IPOs, and exit planning. Her leadership roles at companies such as Maxwellia, Kesmalea Therapeutics, and Psioxus Therapeutics have equipped her with expertise in scaling operations and securing funding. She brings strong governance expertise from Non-Executive Director roles at Nuformix plc, Heartbeat CIC, and Tetris Pharma. She is currently also CFO at PBD Biotech and Fermtech.
'I am excited to join Llusern Scientific at this crucial stage of its development,' said Maddy Kennedy, Chief Financial Officer of Llusern Scientific. 'With its innovative Lodestar DX system poised for expansion into new markets, I look forward to supporting Llusern's growth and overseeing the financial operations needed to achieve its global ambitions.'
Mark Preston joins Llusern Scientific as Chief Technology Officer, bringing extensive expertise in biotech, data analytics, and cloud technologies. As CTO, Mark will lead the development of Lodestar DX overseeing technological innovation, scalability, and compliance. Mark's early career includes experience in embedded systems and devices at Sony and Panasonic, working on networking hardware, mobile phones, and microscopes. His later work in app development, AI-driven insights, and workflow optimization enabled him to deliver scalable, secure, and compliant solutions for start-ups and global organizations, including vaccine manufacturers. As a Founder and Managing Director of consultancy firm Prismea, Mark helps biotech companies innovate with data analytics, cloud systems, and regulatory compliance as well as navigating medical regulatory frameworks with organizations such as the MHRA.
'I've been impressed by the Lodestar DX system and its ability to deliver treatment directing diagnosis of UTIs at the point of care,' said Mark Preston, Chief Technology Officer. 'I look forward to supporting the company's efforts to bring precision diagnostics to healthcare settings worldwide.'
Emma Hayhurst, Co-founder and CEO of Llusern Scientific, commented:'We are thrilled to welcome Bob, Maddy, and Mark to our executive leadership team. Their deep expertise in urology, finance, and technology will be instrumental in ensuring Llusern remains at the forefront of providing precise, accessible diagnostic solutions that deliver improved outcomes for patients suffering from UTIs.'
Notes to Editors
About Llusern ScientificLlusern Scientific is a treatment-directing molecular diagnostics company, developing fast, accurate, and accessible tools to guide real-time clinical decision-making at the point-of-care. Our flagship solution, Lodestar DX, is a portable diagnostic device that delivers lab-accurate results for urinary tract infections (UTIs) in around half an hour. It is based on isothermal LAMP technology (not PCR) without the need for DNA extraction or centralized lab infrastructure. With industry-leading sensitivity and specificity, Lodestar DX empowers clinicians to diagnose and treat specific microbial infections with precision in a single visit, thereby improving patient outcomes. As well as providing guidance on the best treatment option based on the specific microbial infection, Lodestar DX also provides a clear 'rule-out' decision where antibiotics are not necessary, helping to reduce antimicrobial resistance through antibiotic stewardship.
Building on success in the UK, Llusern is preparing for commercial launches across India and the MENA region in 2025 and the US in 2026. Llusern is committed to transforming diagnostic pathways and making precision medicine equitable, portable, and fast. Due to its small size and ease of portability Lodestar DX is particularly suitable for resource limited and decentralised healthcare settings including care homes, mobile diagnostics, and community diagnostic centres. Additionally Lodestar DX has uses within paediatrics, urology, and other secondary care settings.
The Lodestar DX UTI testing system has been independently evaluated in studies by University of Oxford, Norfolk and Norwich University Hospital, Southampton University, and Public Health Wales. The company was established in 2020 as a spin-out from the University of South Wales, UK.
For more information, visit https://llusern.co.uk/ and follow us on LinkedIn.
Media Contacts
Llusern ScientificMartyn Lewis +44 (0) 7825 708936martyn@llusern.co.uk
Scius CommunicationsKatja Stout +44 (0) 7789435990katja@sciuscommunications.com
Daniel Gooch +44 (0) 7747875479daniel@sciuscommunications.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Official: Deportivo Alavés star seals €16m Ligue 1 switch
La Liga outfit Deportivo Alavés have this weekend secured for themselves a significant cash injection. This comes after attacker Joaquín Panichelli's long-rumoured departure from the club was finally made official. Panichelli, for his part, spent this past season out on loan away from Alavés. Not yet considered ready to be a regular contributor at Mendizorroza, the Argentine made the move to Spain's 2nd tier, with CD Mirandés. And to say that Panichelli went on to enjoy a productive stint on the books of Mirandés would be putting it lightly… All told, across 44 appearances in La Liga 2, the 22-year-old racked up a head-turning 29 direct goal contributions. Such exploits did not go unnoticed across the continent, with Ligue 1 outfit Strasbourg, for one, having recently opened talks with their Alavés counterparts in an effort to beat out the stiff competition for Panichelli's signature. And as alluded to above, this weekend, such negotiations have officially borne fruit. As per a statement across Alavés' website and social media platforms on Sunday: 'Deportivo Alavés and RC Strasbourg Alsace have reached an agreement for the transfer of striker Joaquín Panichelli to the French club.' According to transfer insider , Panichelli's move to France has come at a cost of around €16.5 million. Conor Laird – GSFN
Yahoo
an hour ago
- Yahoo
'Here we go soon' – Liverpool Close to Agreeing £65m Deal for Forward
Luis Díaz Nears Bayern Munich Move: What It Means for Liverpool's Future In a significant development in Liverpool's summer transfer window, Fabrizio Romano reports that Luis Díaz is on the verge of joining Bayern Munich, with a deal nearing completion. The Colombian winger, a fan favourite at Anfield, is set to swap Merseyside for Bavaria in a move valued at €75 million, including add-ons. The contract would run until June 2029, with only final details around performance-related bonuses now left to settle. Romano tweeted: ' FC Bayern are closing in on deal to sign Luis Diaz from Liverpool! Agreement at final stages with details being sorted. €75m package with add-ons included, contract until June 2029. Liverpool and Bayern are discussing add-ons details… then, here we go soon. ' This transfer, while not wholly unexpected, marks another pivotal moment in what has already been a turbulent summer for Liverpool. Under new manager Arne Slot, the club is navigating a major transition, both tactically and emotionally, following the departure of Jurgen Klopp and the recent tragic loss of Diogo Jota. Díaz's exit signals the continuation of an era-defining squad overhaul. Diaz's Liverpool Legacy Luis Díaz arrived from FC Porto in January 2022 and made an immediate impact. Known for his direct running, flair and relentless work ethic, he became an essential part of Klopp's system, especially during the club's push for a quadruple in the 2021-22 season. However, injuries and inconsistent form in recent campaigns saw his influence wane slightly, opening the door for discussions about his long-term role. Still, losing Díaz is a blow. His contribution in high-pressure moments, particularly in cup competitions, helped Liverpool maintain competitiveness during squad transitions. The €75 million fee represents decent value, but reinvestment will be critical. What This Means for Arne Slot Slot is tasked with evolving Liverpool's tactical identity and is reportedly open to reshaping the attacking unit. With Darwin Núñez also likely to depart, the club's frontline could be unrecognisable come September. Reports suggest Newcastle's Alexander Isak is the dream replacement, though the fee required could surpass £100 million. This puts pressure on sporting director Richard Hughes and the recruitment team to ensure that Díaz's departure is not merely a cash-raising exercise, but part of a broader strategic vision. The attack now lacks a left-sided option who can cut inside and threaten consistently. Harvey Elliott's future is also under question, meaning Liverpool could be preparing for a near-complete forward rebuild. Market Implications Díaz's move to Bayern shifts the balance across Europe too. Bayern, coming off a trophyless season, are eager to refresh their squad, and Díaz offers them pace and flair that has been missing. His signing fits the Bundesliga giants' model of acquiring Premier League-tested talent to reassert domestic and continental dominance. For Liverpool, it is yet another reminder that the rebuild under Arne Slot will be aggressive and possibly painful. With experienced players leaving and major gaps to fill, the Anfield hierarchy will need to move swiftly and decisively in the market. Our View – Anfield Index Analysis From a Liverpool fan's perspective, this feels like the start of a full reset. Díaz leaving for Bayern is logical in terms of business, but emotionally, it hurts. He gave us moments of brilliance, particularly when we were short of inspiration, and there's a sense of unfinished business given the injuries and system changes that hampered him. There's also concern about the volume of outgoings. Losing Diogo Jota was heartbreaking. Now with Díaz going and Darwin Núñez expected to follow, the attack that once terrified Europe is being dismantled. If Elliott goes too, we are looking at a complete rebuild under a new manager in his first Premier League season. Yes, Alexander Isak would be a huge statement signing. But that doesn't change the fact that we'll be missing Díaz's dribbling, directness and energy in the left channel. Isak is a different kind of player, and Slot will need to adjust tactically. What's worrying is the timing. We're just weeks from the new season, and our attack is threadbare. Fans will back the manager, but the owners and new sporting structure must show real ambition now. Selling Díaz is acceptable if it leads to smart, fast reinvestment. If not, the project risks starting on the back foot.
Yahoo
an hour ago
- Yahoo
Labcorp Holdings Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Labcorp Holdings (NYSE:LH) Second Quarter 2025 Results Key Financial Results Revenue: US$3.53b (up 9.5% from 2Q 2024). Net income: US$237.9m (up 16% from 2Q 2024). Profit margin: 6.7% (up from 6.4% in 2Q 2024). The increase in margin was driven by higher revenue. EPS: US$2.85 (up from US$2.44 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Labcorp Holdings Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 12%. Looking ahead, revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Healthcare industry in the US. Performance of the American Healthcare industry. The company's shares are up 8.7% from a week ago. Risk Analysis You should learn about the 2 warning signs we've spotted with Labcorp Holdings. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
